Table 1 Overview of in vivo studies of the effect of STF on the toxicity and/or efficacy of chemotherapy, radiotherapy and tyrosine kinase inhibitors
Author | Strain | Treatment | Outcomes of STF |
|---|---|---|---|
Raffaghello et al. 2008 [19] | A/J, CD-1, nude mice and A/J mice bearing subcutaneous NXS2 neuroblastoma | High dose etoposide ± 48–60 h STF | Decreased mortality (toxicity) after high dose etoposide |
Lee et al. 2012 [12] | BALB/c, C57BL/6 and nude mice bearing subcutaneous: | ±48–60 h STF and: |  |
4 T1 breast cancer | Cyclophosphamide | Increased efficacy of CT, STF alone was as effective as CT alone, Increased survival | |
B16 melanoma | Doxorubicin | Increased efficacy of CT, Increased survival, Decreased metastasis | |
GL26 glioma | Doxorubicin | Increased efficacy of CT STF alone was as effective as CT alone | |
ACN human neuroblastoma | Doxorubicin | Increased efficacy of CT | |
MDAMB-231 breast cancer | Doxorubicin | Increased efficacy of CT | |
OVCAR3 ovarian cancer | Doxorubicin | Increased efficacy of CT | |
NXS2 neuroblastoma | Only STF | STF alone was effective, Increased survival | |
Safdie et al. 2012 [13] | C57BL/6 N mice bearing subcutaneous or intracranial GL26 glioma | Temozolomide ± 48 h STF | Increased efficacy of CT, STF alone was as effective as CT alone (subcutaneous model only) |
Radiotherapy ± 48 h STF | Increased efficacy of radiotherapy | ||
Shi et al. 2012 [37] | CD-1 Nude mice bearing subcutaneous ZL55 mesothelioma and A549 lung carcinoma | Cisplatin ±48 h STF | Increased efficacy of CT, STF alone was more effective as CT alone (mesothelioma only) |
Kawaguchi et al. 2012 [62] | GFP-LC3 mice | Doxorubicin ±48 h STF | Decreased cardiotoxicity after high dose doxorubicin. |
Brandhorst et al. 2013 [18] | AIN93G mice | High dose doxorubicin ±60 h STF | Decreased mortality (toxicity) after high dose doxorubicin. |
Saleh et al. 2013 [38] | BALB/c mice bearing subcutaneous 67NR or NIH3 triple negative breast cancer | Radiotherapy ± 24 h STF (alternate) | Increased efficacy of radiotherapy |
Cheng et al. 2014 [22] | C57BL/6 J mice | Cyclophosphamide ± 48 h STF | Decreased mortality (toxicity) after high dose cyclophosphamide. |
Bianchi et al. 2015 [14] | BALB/c mice bearing subcutaneous CT26 colon cancer | Oxaliplatin ± 48 h STF | Increased efficacy of CT |
Shim et al. 2015 [15] | C57BL/6 J mice bearing subcutaneous B16 melanoma | Doxorubicin or Cyclophosphamide ± 48 h STF | Increased efficacy of CT STF alone was as effective as CT alone |
D’Aronzo et al. 2015 [36] | Nu/Nu mice bearing subcutaneous BxPC-3-luc pancreatic cancer | Gemcitabine ± 24 h STF | Increased efficacy of CT |
Huisman et al. 2015 [20] | FabplCre;Apc15lox/C mice bearing spontaneous intestinal malignancies | Irinotecan ± 48 h STF | Decreased toxicity to CT No effect on efficacy of CT |
Tinkum et al. 2015 [21] | B6(Cg)-Tyrc-2 J/J, Bmi1CreERT/+;Rosa26R/+ HopXCreERT/+;Rosa26R/+ Lgr5EGFP-IRES-CreERT2/+;Rosa26R/+, Lgr5EGFP-IRES-CreERT2/+ mice | High dose etoposide ± 24 h STF | Decreased mortality (toxicity) after high dose etoposide |
Caffa et al. 2015 [39] | BALB/c mice bearing subcutaneous H3122 lung cancer or HCT116 colorectal cancer | Crizotinib/regorafinib ± 48 h STF | Increased efficacy of crizotinib/regorafinib |
Huisman et al. 2015 [23] | BALB/c mice bearing subcutaneous C26 colon cancer | Irinotecan ± 72 h STF | Decreased toxicity to CT No effect on efficacy of CT |
Di Biase et al. 2016 [16] | BALB/c, BALB/c-nude and C57BL/6 mice bearing subcutaneous MCF7 and 4T1 breast cancer, B16 melanoma | Doxorubicin and cyclophosphamide ±48 h STF or 96 h FMD | Increased efficacy of CT |
Pietrocola et al. 2016 [40] | Wild-type C57BL/6 and athymic (nu/nu) mice | Mitoxantrone or oxaliplatin ± 48 h STF | Increased efficacy of CT |
Di Biase et al. 2017 [17] | C57BL/6 mice | Doxorubicin ±24–72 h STF | Decreased cardiotoxicity after high dose doxorubicin. |
Jongbloed et al. 2019 [24] | BALB/c mice | Irinotecan ± 72 h STF | Decreased toxicity to CT |
Authors, site | Subjects | Treatment | Outcome of STF |
Withers et al. 2014, UC Davis, USA [63] | 20 dogs with lymphoma | Doxorubicin ±24 h STF | Safe and feasible Reduction in vomiting No reduction in IGF-1 |